Potential Drug Interactions Between cART and New Psychoactive Substances

Hentig, Nils von

doi:10.4172/jaa.1000e131

Cited by 2 publications

(4 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Desired and untoward effects were described to be comparable to those observed with other stimulant-type drugs (e.g., MDMA, mephedrone) characterized by similar pharmacological properties (Brandt, Baummann, et al, 2014;McLaughlin et al, 2014;Schifano et al, 2015Schifano et al, , 2016Hentig, 2016;Lucchetti, Marzo, Di Clemente, Cervo, & Gobbi, 2016).…”

Section: Methodsmentioning

confidence: 84%

“…Published information on ROAs suggests that nasal insufflation and oral consumption practices are the most widely used followed by inhalation and injection (ACMD, ; EMCDDA, ; EMCDDA, ; Cosbey et al, ; Coppola & Mondola, ; Glanville, Dargan, & Wood, ; Hentig, ).…”

Section: Resultsmentioning

confidence: 99%

“…Oral doses were described ranging from 10 to 200 mg, although the insufflated ones vary from 10 to 65 mg (ACMD, ; Coppola & Mondola, ; EMCDDA, ; EMCDDA, ; Glanville et al, ; Hentig, ; Nizar, Dargan, & Wood, ).…”

Section: Resultsmentioning

confidence: 99%

“…Combination with other drugs (e.g., synthetic cathinones, amphetamines, and cocaine) has been widely reported and accounted for several toxicity events (e.g., cardiovascular effects, psychotic symptoms, and agitation hyperthermia) and fatalities (ACMD, 2014;Berg, 2016;Brandt, King, et al, 2014;Coppola & Mondola, 2015;Cosbey et al, 2014;EMCDDA, 2014;EMCDDA, 2015;Glanville et al, 2015;Hentig, 2016).…”

Section: Methodsmentioning

confidence: 99%

See 3 more Smart Citations

4,4′‐Dimethylaminorex (“4,4′‐DMAR”; “Serotoni”) misuse: A Web‐based study

Loi

Zloh

Luca

et al. 2017

Human Psychopharmacology

View full text Add to dashboard Cite

Background 4,4′‐DMAR (4,4′‐dimethylaminorex; “Serotoni”) is a potent stimulant drug that has recently been associated with a number of fatalities in Europe. Over the last few years, online communities have emerged as important resources for disseminating levels of technical knowledge on novel psychoactive substances. Objective Analysing the information provided by the fora communities on 4,4′‐DMAR use, additionally critical reviewing the available evidence‐based literature on this topic. Methods Different website drug fora were identified. A critical review of the existing evidence‐based literature was undertaken. Individuation and analysis of qualitative data from the identified website fora were performed. Results The combined search results identified six website fora from which a range of qualitative data on recurring themes was collected. These themes included routes of administration and doses; desired effects; adverse effects; comparison with other drugs; association with other drugs; medications self‐administered to reverse 4,4′‐DMAR action; overall impression; and provision of harm‐reduction advice. Conclusions Although being characterized by a number of methodological limitations, the social networks' Web monitoring approach (netnography) may be helpful to better understand some of the clinical and psychopharmacological issues pertaining to a range of novel psychoactive substances, including 4,4′‐DMAR, for which only extremely little, if any, scientific knowledge is available.

show abstract

Section: Methodsmentioning

confidence: 84%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

4,4′‐Dimethylaminorex (“4,4′‐DMAR”; “Serotoni”) misuse: A Web‐based study

Loi

Zloh

Luca

et al. 2017

Human Psychopharmacology

View full text Add to dashboard Cite

show abstract

Brain opportunistic infections and tumors in people living with HIV — still a challenge in efficient antiretroviral therapy era

et al. 2023

View full text Add to dashboard Cite

The aim of the study was to evaluate the incidence of brain opportunistic pathologies and survival in patients living with HIV from a Romanian tertiary center. A 15-year prospective observational study of brain opportunistic infections diagnosed in HIV-infected patients was performed at Victor Babes Hospital, Bucharest, between January 2006 and December 2021. Characteristics and survival were compared related to modes of HIV acquisition and type of opportunistic infection. A total of 320 patients were diagnosed with 342 brain opportunistic infections (incidence 9.79 per 1000 person-years), 60.2% males with median age at diagnosis of 31 years (IQR 25, 40). Median CD4 cell count and VL were 36/μL (IQR 14, 96) and 5.1 log 10 copies/mL (IQR 4, 5.7) respectively. The routes of HIV acquisition were heterosexual (52.6%), parenteral route in early childhood (31.6%), injecting drug use (12.9%), men having sex with men (1.8%), and vertical (1.2%). The most common brain infections were progressive multifocal leukoencephalopathy (31.3%), cerebral toxoplasmosis (26.9%), tuberculous meningitis (19.3%), and cryptococcal meningitis (16.7%). Patients infected by parenteral mode in early childhood were younger at diagnosis of both opportunistic infection and HIV ( p < 0.001 and p < 0.001, respectively), developed more frequently PML ( p < 0.001), and had the lowest early ( p = 0.002) and late ( p = 0.019) mortality rates. Risk factors for shorter survival were age > 30 years ( p = 0.001), injecting drug use ( p = 0.003), CD4 + < 100/μL ( p = 0.007), and VL > 5 log 10 copies/mL at diagnosis ( p < 0.001). The incidence and mortality rate of brain opportunistic infections were high and did not decrease significantly during the study period, due to late presentation or non-adherence to ART.

show abstract

Potential Drug Interactions Between cART and New Psychoactive Substances

Cited by 2 publications

References 23 publications

4,4′‐Dimethylaminorex (“4,4′‐DMAR”; “Serotoni”) misuse: A Web‐based study

4,4′‐Dimethylaminorex (“4,4′‐DMAR”; “Serotoni”) misuse: A Web‐based study

Brain opportunistic infections and tumors in people living with HIV — still a challenge in efficient antiretroviral therapy era

Contact Info

Product

Resources

About